MEX3A and colorectal carcinoma: Moreover, KM analysis indicated that high expression of MEX3A correlated with a poor prognosis in patients with CRC (OS, HR:3.05 95% CI 1.91–4.87, P < 0.001; RFS, HR:3.23 95% CI 1.71–6.19, P < 0.001, respectively) (Fig. 2G and H).